AU2004249167A1 - Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis - Google Patents

Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis Download PDF

Info

Publication number
AU2004249167A1
AU2004249167A1 AU2004249167A AU2004249167A AU2004249167A1 AU 2004249167 A1 AU2004249167 A1 AU 2004249167A1 AU 2004249167 A AU2004249167 A AU 2004249167A AU 2004249167 A AU2004249167 A AU 2004249167A AU 2004249167 A1 AU2004249167 A1 AU 2004249167A1
Authority
AU
Australia
Prior art keywords
formulations
steroidal anti
edema
retinal
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004249167A
Other languages
English (en)
Inventor
David P. Bingaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU2004249167A1 publication Critical patent/AU2004249167A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004249167A 2003-06-13 2004-06-14 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis Abandoned AU2004249167A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47822703P 2003-06-13 2003-06-13
US47825203P 2003-06-13 2003-06-13
US60/478,252 2003-06-13
US60/478,227 2003-06-13
PCT/US2004/018792 WO2004112772A1 (en) 2003-06-13 2004-06-14 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis

Publications (1)

Publication Number Publication Date
AU2004249167A1 true AU2004249167A1 (en) 2004-12-29

Family

ID=33544369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004249167A Abandoned AU2004249167A1 (en) 2003-06-13 2004-06-14 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis

Country Status (10)

Country Link
US (2) US20070043006A1 (enExample)
EP (1) EP1633339A4 (enExample)
JP (1) JP2007500250A (enExample)
KR (1) KR20060019579A (enExample)
AU (1) AU2004249167A1 (enExample)
BR (1) BRPI0411427A (enExample)
CA (1) CA2527121A1 (enExample)
MX (1) MXPA05012696A (enExample)
RU (1) RU2006101150A (enExample)
WO (1) WO2004112772A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635842A4 (en) * 2003-06-20 2007-04-04 Alcon Inc TREATMENT OF AMD WITH A COMBINATION OF INGREDIENTS
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
ES2667945T3 (es) * 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
CA1331559C (en) * 1986-04-21 1994-08-23 Jon Joseph Kabara Antimicrobial preservative compositions and methods
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
EP0533703B1 (en) * 1990-06-11 2000-03-15 Alcon Laboratories, Inc. Use of steroids for the inhibition of angiogenesis
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO1997041867A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
PT1221918E (pt) * 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
KR100732262B1 (ko) * 1999-10-21 2007-06-25 알콘, 인코퍼레이티드 약물 전달 장치
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
US6646003B2 (en) * 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac

Also Published As

Publication number Publication date
KR20060019579A (ko) 2006-03-03
US20040259765A1 (en) 2004-12-23
US20070043006A1 (en) 2007-02-22
RU2006101150A (ru) 2006-06-10
EP1633339A1 (en) 2006-03-15
WO2004112772A1 (en) 2004-12-29
BRPI0411427A (pt) 2006-07-25
CA2527121A1 (en) 2004-12-29
EP1633339A4 (en) 2009-06-03
JP2007500250A (ja) 2007-01-11
MXPA05012696A (es) 2006-02-22

Similar Documents

Publication Publication Date Title
Jonas Intravitreal triamcinolone acetonide for diabetic retinopathy
JP2009511604A (ja) 緑内障の原発性形態および続発性形態を処置するための方法
CA2738151C (en) Eye drop with difluprednate for macular edema treatment
US20070134244A1 (en) Combination treatment for pathologic ocular angiogenesis
US20060154910A1 (en) Use of steroids to treat ocular disorders
CN100431544C (zh) 用于治疗病理性眼血管生成的糖皮质激素制剂
AU2015355289A1 (en) Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US20040259765A1 (en) Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
JP2007500250A5 (enExample)
Bodaghi et al. Comparison of the efficacy and safety of two formulations of diclofenac sodium 0.1% eyedrops in controlling postoperative inflammation after cataract surgery
ZA200509532B (en) Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
Fante et al. Cystoid macular edema
MXPA04007802A (es) Tratamiento de desordenes oftalmicos utilizando urea o derivados de urea.
Amol The Posurdex biodegradable intravitreal extended-release implant
DeStafeno et al. Perioperative and Postoperative Medications
US20090181933A1 (en) Use of steroids to treat persons suffering from ocular disorders
CN1802151A (zh) 用于治疗病理性眼内血管生成的非甾体类抗炎药制剂
Ahuja et al. Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study
Yoo The true impact of ocular inflammation on refractive cataract surgery outcomes
JP2009521511A (ja) 濾過胞手術間の補助としての酢酸アネコルタブの使用
HK40068749A (en) Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
MX2008007884A (en) Use of anecortave acetate as an adjunct during filtration bleb surgery

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application